Invesco S&P MidCap 400 GARP ETF
GRPM - ETF AI Analysis
Top Page
Invesco S&P MidCap 400 GARP ETF (GRPM)
GRPM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 623.28M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.84
- Issuer
- Invesco
- Inception Date
- Dec 08, 2010
- Dividend Yield
- 0.54%
- Asset Class
- Equity
- Index Tracked
- S&P MidCap 400 GARP Index - USD - Benchmark TR Gross
GRPM Summary
The Invesco S&P MidCap 400 GARP ETF (GRPM) follows the S&P MidCap 400 GARP Index, focusing on mid-sized U.S. companies that aim for growth at a reasonable price. It spreads your money across many sectors, including financials, technology, and health care, and holds well-known names like Abercrombie & Fitch and DocuSign. Someone might invest in GRPM to seek long-term growth while staying diversified across different industries and avoiding only the biggest or smallest companies. A key risk is that mid-cap stocks can still be quite volatile, so the value of this ETF can go up and down with the stock market.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 invested. That’s a bit higher than the cheapest index ETFs because it follows a more specialized, rules-based GARP strategy rather than a plain-vanilla passive index.
What would affect this ETF?
GRPM could benefit if the U.S. economy continues to grow, supporting mid-sized companies in technology, health care, and consumer sectors, and if interest rates stabilize or fall, which can help both growth stocks and financial firms. On the downside, higher interest rates, slower U.S. growth, or tighter regulations on financial and tech companies could hurt its performance, and shifts in consumer spending could negatively affect holdings like Abercrombie & Fitch and SharkNinja.
GRPM Top 10 Holdings
GRPM is leaning heavily into U.S. mid-cap growth stories, with tech and health care names doing much of the heavy lifting. Cybersecurity player Qualys and contract research firm Medpace are rising steadily, helping power returns, while Halozyme and SharkNinja add more momentum from the health care and consumer side. On the flip side, Duolingo and AppFolio have been mixed to lagging, occasionally acting like sandbags on the portfolio. Overall, the fund is diversified across sectors but clearly tilted toward innovative, growth-focused U.S. companies.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ANF | Abercrombie Fitch | 3.38% | $20.63M | $6.53B | 114.87% | 78Outperform |
 DUOL | Duolingo | 3.06% | $18.66M | $7.39B | -18.74% | 69Neutral |
 SN | SharkNinja, Inc. | 2.79% | $17.03M | $31.92B | 138.97% | 76Outperform |
 HALO | Halozyme | 2.71% | $16.52M | $11.74B | 51.42% | 73Outperform |
 APPF | AppFolio | 2.66% | $16.21M | $7.97B | -11.84% | 71Outperform |
 PCTY | Paylocity | 2.63% | $16.06M | $9.30B | 25.79% | 71Outperform |
 RNR | Renaissancere Holdings | 2.46% | $15.03M | $14.38B | 32.98% | 78Outperform |
 KNSL | Kinsale Capital Group | 2.45% | $14.96M | $8.95B | 1.70% | 75Outperform |
 MEDP | Medpace Holdings | 2.43% | $14.81M | $18.59B | 10.68% | 79Outperform |
 EXEL | Exelixis | 2.36% | $14.40M | $17.22B | 70.44% | 78Outperform |
GRPM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPM, the sentiment is Positive. The current price of 146.13 is above the 20-day moving average (MA) of 144.17, above the 50-day MA of 141.22, and above the 200-day MA of 130.90, indicating a bullish trend. The MACD of 1.68 indicates Negative momentum. The RSI at 56.74 is Neutral, neither overbought nor oversold. The STOCH value of 29.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPM.
GRPM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GRPM | $146.13 | $161.00(10.18% Upside) | $623.28M | 0.35% | 74Outperform |
 EZM | $75.71 | $85.64(13.12% Upside) | $954.82M | 0.38% | 70Neutral |
 XMLV | $67.12 | $73.85(10.03% Upside) | $733.37M | 0.25% | 71Outperform |
 BKMC | $39.69 | $47.33(19.25% Upside) | $657.20M | 0.04% | 68Neutral |
 AVMC | $79.28 | $93.23(17.59% Upside) | $560.29M | 0.18% | 70Outperform |
 JPME | $126.07 | $139.69(10.81% Upside) | $497.74M | 0.24% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GRPM | Invesco S&P MidCap 400 GARP ETF | 146.13 | 27.81 | 23.50% | |
| EZM | WisdomTree U.S. MidCap Fund | 75.71 | 10.63 | 16.34% | |
| XMLV | Invesco S&P MidCap Low Volatility ETF | 67.12 | 5.74 | 9.35% | |
| BKMC | BNY Mellon US Mid Cap Core Equity ETF | 39.69 | 4.02 | 11.28% | |
| AVMC | Avantis U.S. Mid Cap Equity ETF | 79.28 | 9.96 | 14.36% | |
| JPME | JPMorgan Diversified Return U.S. Mid Cap Equity ETF | 126.07 | 19.84 | 18.68% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.